Description

This opportunity provides funding for investigational new drug (IND)-enabling studies and early-phase clinical trials for pharmacological interventions and devices aimed at Alzheimer’s disease and related dementias. The program emphasizes novel drug mechanisms and therapeutic modalities linked to the biology of aging, including small molecules, peptides, antibodies, gene therapies, antisense oligonucleotides, and stem cells. High-priority areas include combination therapies, disease-modifying and symptomatic agents, and mechanisms involving epigenetics, inflammation, mitochondrial function, neuroprotection, proteostasis, synaptic activity, and vascular function. Proposals must present a strong scientific rationale, preliminary data, and a clear justification for the clinical population and study design. Anti-amyloid and cholinesterase inhibitor approaches are excluded.